Jennison Associates’s Apogee Therapeutics APGE Stock Holding History

Jennison Associates’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$964K	Sell	7,265 -577,751	-99%	-$52.1M	﹤0.01%	507
2026 Q1	$49.2M	Buy	585,016 +6,389	+1%	+$464K	0.03%	223
2025 Q4	$43.7M	Buy	+578,627	New	+$36.4M	0.03%	232
2025 Q3	–	Sell	-270,366	Closed	-$11.7M	–	568
2025 Q2	$11.7M	Sell	270,366 -23,391	-8%	-$890K	0.01%	369
2025 Q1	$11M	Sell	293,757 -18,634	-6%	-$720K	0.01%	376
2024 Q4	$14.2M	Sell	312,391 -220	-0.1%	-$11.2K	0.01%	370
2024 Q3	$18.4M	Buy	312,611 +6,533	+2%	+$313K	0.01%	350
2024 Q2	$12M	Buy	306,078 +3,186	+1%	+$155K	0.01%	370
2024 Q1	$20.1M	Buy	302,892 +199,148	+192%	+$8.69M	0.01%	341
2023 Q4	$2.9M	Buy	+103,744	New	+$2.08M	﹤0.01%	441

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Jennison Associates's APGE Position: Q2 2026 in Review

Jennison Associates reduced its Apogee Therapeutics (APGE) stake by 99% in Q2 2026, selling an estimated $52.1M and leaving 7,265 shares worth $964K. The position accounts for ﹤0.01% of the portfolio, ranked #507.

Jennison Associates first reported a position in APGE in Q4 2023 and has held it in 10 quarters since. The position peaked at $49.2M in Q1 2026. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Jennison Associates held 7,265 shares of Apogee Therapeutics worth $964K as of Q2 2026.
Jennison Associates sold 577,751 Apogee Therapeutics shares in Q2 2026, an estimated $52.1M.
Apogee Therapeutics made up ﹤0.01% of Jennison Associates's portfolio in Q2 2026, its #507 holding.
Jennison Associates first reported a position in Apogee Therapeutics in Q4 2023 and has held it in 10 quarters since.
Jennison Associates's Apogee Therapeutics position peaked at $49.2M in Q1 2026.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.